Amphastar Pharmaceuticals, Inc. (AMPH) Bundle
Understanding Amphastar Pharmaceuticals, Inc. (AMPH) Revenue Streams
Understanding Amphastar Pharmaceuticals, Inc.’s Revenue Streams
The primary revenue sources for Amphastar Pharmaceuticals, Inc. include finished pharmaceutical products and active pharmaceutical ingredients (APIs). The company has diversified its revenue by expanding its product offerings and entering new markets.
Revenue Breakdown by Segment
| Segment | Q3 2024 Revenue (in thousands) | Q3 2023 Revenue (in thousands) | Change (Dollars) | Change (%) |
|---|---|---|---|---|
| Finished Pharmaceutical Products | $187,357 | $147,665 | $39,692 | 27% |
| Active Pharmaceutical Ingredients (API) | $1,462 | $4,190 | ($2,728) | (65%) |
| Total Product Revenues | $188,819 | $151,855 | $36,964 | 24% |
| Other Revenues | $2,395 | $28,701 | ($26,306) | (92%) |
| Total Net Revenues | $191,214 | $180,556 | $10,658 | 6% |
Year-over-Year Revenue Growth Rate
For the nine months ended September 30, 2024, total net revenues were $545,444 thousand, compared to $466,290 thousand for the same period in 2023, reflecting a 17% increase.
Contribution of Different Business Segments to Overall Revenue
In the nine months ended September 30, 2024, the contribution of finished pharmaceutical products to total revenues was $519,147 thousand, representing a 22% increase from $426,541 thousand in 2023. In contrast, API revenues contributed $6,689 thousand, down 39% from $11,048 thousand in 2023.
Significant Changes in Revenue Streams
The introduction of BAQSIMI® significantly impacted revenue, contributing $85,106 thousand in the nine months ended September 30, 2024. This product was not part of the revenue stream in the previous year. Additionally, the transition of distribution responsibilities for BAQSIMI® from Lilly to Amphastar allowed for the recognition of $40.4 million in sales during the third quarter of 2024, marking a notable shift in revenue dynamics.
Conversely, the revenue from APIs has declined primarily due to lower customer purchases as MannKind, the largest customer, is qualifying upgraded products, which will affect sales for the next two years.
Conclusion
The revenue analysis of Amphastar Pharmaceuticals illustrates a strong growth trajectory in finished pharmaceutical products, driven by strategic product launches and market expansions, while API revenues face challenges due to customer qualification processes.
A Deep Dive into Amphastar Pharmaceuticals, Inc. (AMPH) Profitability
Profitability Metrics
Gross Profit Margin: For the three months ended September 30, 2024, gross profit was $101,941,000 with a gross profit margin of 53%. In comparison, for the same period in 2023, gross profit was $108,403,000 with a margin of 60%.
Net Profit Margin: The net income for the three months ended September 30, 2024, was $40,429,000, translating to a net profit margin of 21.1%. For the same period in 2023, net income was $49,222,000, resulting in a net profit margin of 27.3%.
Operating Profit: Operating income for the three months ended September 30, 2024, was $57,048,000 compared to $72,678,000 in 2023, indicating a decrease in operating profit margin from 40.3% to 29.9%.
Trends in Profitability Over Time
Over the nine months ended September 30, 2024, total net revenues were $545,444,000, up by 17% from $466,290,000 in 2023. Gross profit increased to $287,207,000 from $254,981,000, representing a 13% rise. However, the gross margin decreased from 55% to 53%.
Comparison of Profitability Ratios with Industry Averages
The average gross profit margin in the pharmaceutical industry typically ranges from 60% to 80%, indicating that the company's gross profit margin is below industry averages. Similarly, the net profit margin in the industry averages around 20% to 25%, positioning the company on the lower end of the spectrum.
Analysis of Operational Efficiency
In terms of cost management, total operating expenses for the nine months ended September 30, 2024, totaled $126,932,000, compared to $111,974,000 in the previous year, marking a 13.4% increase. Selling, distribution, and marketing expenses rose by 35% to $27,378,000, while general and administrative expenses increased by 14% to $43,782,000.
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Gross Profit | $101,941,000 | $108,403,000 | -6% |
| Operating Income | $57,048,000 | $72,678,000 | -22% |
| Net Income | $40,429,000 | $49,222,000 | -18% |
| Gross Profit Margin | 53% | 60% | -7% |
| Net Profit Margin | 21.1% | 27.3% | -6.2% |
The increase in operational costs has been driven by higher labor costs and increased expenses related to marketing and distribution efforts, particularly for new product lines. This reflects a strategic investment aimed at enhancing market presence despite the immediate impact on profitability metrics.
Debt vs. Equity: How Amphastar Pharmaceuticals, Inc. (AMPH) Finances Its Growth
Debt vs. Equity: How Amphastar Pharmaceuticals Finances Its Growth
Overview of the Company's Debt Levels
As of September 30, 2024, the total debt of the company stood at $609.2 million, which includes both short-term and long-term obligations. The breakdown is as follows:
| Debt Type | Amount (in thousands) |
|---|---|
| 2029 Convertible Notes | $345,000 |
| Wells Fargo Term Loan due June 2028 | $250,000 |
| Other Loans | $13,565 |
| Equipment under Finance Leases | $485 |
| Total Debt | $609,218 |
The long-term debt, net of current portion and unamortized debt issuance costs, is $596.4 million.
Debt-to-Equity Ratio and Comparison to Industry Standards
The company’s debt-to-equity ratio as of September 30, 2024, is calculated to be 0.84 based on total liabilities of $817.5 million and total equity of $727.7 million. This ratio is below the industry average for pharmaceutical companies, which typically ranges from 1.0 to 1.5.
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
In September 2023, the company issued the 2029 Convertible Notes amounting to $345.0 million at an interest rate of 2.0%. The proceeds were primarily used to repay approximately $200.0 million of borrowings under the Wells Fargo Term Loan and to repurchase $50.0 million of common stock. As of now, the company maintains a credit rating that reflects moderate risk, consistent with its financial strategy.
Balancing Between Debt Financing and Equity Funding
The company employs a balanced approach between debt financing and equity funding. As of September 30, 2024, total equity is reported at $727.7 million, which is a significant increase from $639.4 million in the previous year. The increase in equity is attributed to retained earnings and the issuance of common stock under equity plans.
The company's strategy focuses on leveraging low-interest debt to finance growth while using equity to mitigate risk. The company’s ability to generate cash from operations, which amounted to $184.4 million for the nine months ended September 30, 2024, supports its debt obligations.
Overall, Amphastar Pharmaceuticals continues to manage its debt and equity structure effectively, ensuring financial flexibility to support its growth initiatives.
Assessing Amphastar Pharmaceuticals, Inc. (AMPH) Liquidity
Assessing Amphastar Pharmaceuticals, Inc.'s Liquidity
Current and Quick Ratios
The current ratio for Amphastar Pharmaceuticals, Inc. as of September 30, 2024, is 3.39, calculated from current assets of $1,314.7 million and current liabilities of $386.9 million. The quick ratio is 2.02, indicating a strong liquidity position as it excludes inventory from current assets.
Analysis of Working Capital Trends
Working capital increased to $386.9 million as of September 30, 2024, up from $264.2 million at December 31, 2023, reflecting an increase of $122.7 million or 46.4% over the period. This improvement in working capital signifies better short-term financial health.
Cash Flow Statements Overview
For the nine months ended September 30, 2024, the cash flow from operating activities was $184.4 million, compared to $159.6 million for the same period in 2023. The breakdown is as follows:
| Cash Flow Type | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net income | $121,555 | $101,378 |
| Depreciation and amortization | $47,800 | $36,500 |
| Changes in operating assets and liabilities | ($6,000) | $2,500 |
| Net cash provided by operating activities | $184,362 | $159,639 |
Investing and Financing Cash Flow Trends
Net cash used in investing activities was $89.3 million for the nine months ended September 30, 2024, primarily due to the acquisition of BAQSIMI® ($129 million) and capital expenditures on property, plant, and equipment ($28.6 million).
In financing activities, net cash used was $47.1 million, which included share repurchases of $43.5 million and debt repayment of $8.1 million.
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company reported $9.5 million in cash and cash equivalents held by foreign subsidiaries, which are not available for domestic operations. However, the company expects its cash reserves, operating cash flows, and borrowing capacity will be sufficient to fund operations for at least the next 12 months.
Is Amphastar Pharmaceuticals, Inc. (AMPH) Overvalued or Undervalued?
Valuation Analysis
To assess whether the company is overvalued or undervalued, we will analyze key valuation ratios, stock price trends, dividend yield, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The current P/E ratio is calculated as follows:
- Current Stock Price: $46.63
- Net Income per Share (Diluted, Q3 2024): $0.78
- P/E Ratio: 59.8
Price-to-Book (P/B) Ratio
The P/B ratio is derived from the following data:
- Book Value per Share: $11.99
- P/B Ratio: 3.89
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is calculated as follows:
- Enterprise Value: $1.4 billion
- EBITDA (Last 12 Months): $196 million
- EV/EBITDA Ratio: 7.14
Stock Price Trends
Over the past 12 months, the stock price has exhibited the following trends:
- 12-Month High: $55.00
- 12-Month Low: $35.00
- Current Price: $46.63
Dividend Yield and Payout Ratio
The company currently does not pay a dividend, thus:
- Dividend Yield: 0%
- Payout Ratio: N/A
Analyst Consensus
According to recent analyst ratings:
- Buy Ratings: 8
- Hold Ratings: 2
- Sell Ratings: 0
| Metric | Value |
|---|---|
| P/E Ratio | 59.8 |
| P/B Ratio | 3.89 |
| EV/EBITDA Ratio | 7.14 |
| 12-Month High | $55.00 |
| 12-Month Low | $35.00 |
| Current Stock Price | $46.63 |
| Dividend Yield | 0% |
| Buy Ratings | 8 |
| Hold Ratings | 2 |
| Sell Ratings | 0 |
Key Risks Facing Amphastar Pharmaceuticals, Inc. (AMPH)
Key Risks Facing Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. faces several internal and external risks that could impact its financial health, particularly in the competitive pharmaceutical industry.
Industry Competition
Increased competition in the pharmaceutical sector poses a significant risk. The company reported a decrease in gross profit margins, which fell to 53% for the nine months ended September 30, 2024, down from 55% in the same period of the previous year. This decline is attributed to rising costs in labor and components, as well as increased depreciation and amortization expenses related to acquired assets.
Regulatory Changes
The pharmaceutical industry is highly regulated. Changes in regulations can lead to increased compliance costs and impact product approval timelines. For instance, the company acknowledged potential impacts from the Organization for Economic Co-operation and Development’s Inclusive Framework on Base Erosion and Profit Shifting, although it does not expect significant adverse effects in 2024.
Market Conditions
Fluctuations in market demand can affect revenue. For the nine months ended September 30, 2024, net revenues increased by 17% to $545.4 million from $466.3 million in the prior year. However, volatility in product demand, particularly for certain finished pharmaceutical products, remains a concern.
Operational Risks
Operational risks include supply chain disruptions and reliance on key customers. The company’s major customers, including McKesson and Cardinal Health, represent a significant portion of revenue. For the three months ended September 30, 2024, McKesson accounted for 26% of net revenues. Any disruption in these relationships could significantly impact financial performance.
Financial Risks
Amphastar's financial health is also influenced by its debt levels. As of September 30, 2024, total liabilities stood at $817.5 million, with long-term debt net of current portion at $596.4 million. The company’s interest expense for the nine months was $23.9 million, which poses a risk if cash flows do not support debt servicing.
Mitigation Strategies
To address these risks, Amphastar is focusing on diversifying its product portfolio and increasing sales of higher-margin products. The introduction of BAQSIMI® has contributed significantly to revenues, generating $85.1 million in net revenues for the nine months ended September 30, 2024. Furthermore, the company is enhancing its marketing and sales efforts, particularly for newly acquired products.
| Risk Factor | Description | Recent Impact/Metric |
|---|---|---|
| Industry Competition | Increased competition affecting margins | Gross profit margin decreased to 53% |
| Regulatory Changes | Changes in regulations impacting compliance costs | Minimal expected impact from OECD regulations |
| Market Conditions | Fluctuations in demand for products | Net revenues increased by 17% to $545.4 million |
| Operational Risks | Reliance on key customers for revenue | McKesson accounted for 26% of net revenues |
| Financial Risks | High levels of debt influencing cash flow | Total liabilities of $817.5 million |
Future Growth Prospects for Amphastar Pharmaceuticals, Inc. (AMPH)
Future Growth Prospects for Amphastar Pharmaceuticals, Inc.
Analysis of Key Growth Drivers
Amphastar Pharmaceuticals, Inc. is positioned for growth through a combination of product innovations, market expansions, and strategic acquisitions. A notable driver has been the launch of BAQSIMI®, which generated $85.1 million in net revenues for the nine months ended September 30, 2024, compared to $0 in the prior year.
Additionally, the finished pharmaceutical products segment reported a 22% increase in net revenues, totaling $519.1 million for the same period. The expansion of product lines such as Primatene MIST® and Epinephrine has further contributed, with revenues of $73.1 million and $75.4 million, respectively, for the nine months ended September 30, 2024.
Future Revenue Growth Projections and Earnings Estimates
For the fiscal year 2024, total net revenues are projected to reach $545.4 million, marking a 17% increase from $466.3 million in 2023. The company expects continued revenue growth driven by the successful integration of BAQSIMI® into its product offerings and the anticipated launch of new products, which are expected to enhance overall sales.
Strategic Initiatives or Partnerships That May Drive Future Growth
Amphastar has engaged in strategic partnerships, including a Manufacturing Services Agreement with Lilly, which ensures a stable supply chain for BAQSIMI®. This agreement is crucial as it allows Amphastar to manage product distribution effectively, increasing market penetration.
Furthermore, the Transition Services Agreement with Lilly facilitates a smooth operational transition, helping to optimize marketing and sales strategies. This collaboration is expected to enhance brand visibility and consumer access, leading to higher sales volumes in 2024 and beyond.
Competitive Advantages That Position the Company for Growth
Amphastar's competitive advantages include its established market presence and diversified product portfolio, which includes both finished pharmaceutical products and active pharmaceutical ingredients (APIs). The company has reported a 20% increase in total product revenues, reaching $525.8 million for the nine months ended September 30, 2024.
Moreover, the company's commitment to research and development, with expenditures reaching $55.8 million for the nine months ended September 30, 2024, positions it well for innovation, allowing it to adapt to market trends and consumer needs effectively.
| Key Metrics | 2024 (Projected) | 2023 (Actual) | Change (%) |
|---|---|---|---|
| Total Net Revenues | $545.4 million | $466.3 million | 17% |
| Finished Pharmaceutical Products Revenues | $519.1 million | $426.5 million | 22% |
| BAQSIMI® Revenues | $85.1 million | $0 | N/A |
| Research and Development Expenses | $55.8 million | $53.3 million | 4.7% |
The company's strategic focus on expanding its product lines and enhancing operational efficiencies through partnerships is expected to yield significant growth in the coming years.
Amphastar Pharmaceuticals, Inc. (AMPH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Amphastar Pharmaceuticals, Inc. (AMPH) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Amphastar Pharmaceuticals, Inc. (AMPH)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Amphastar Pharmaceuticals, Inc. (AMPH)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.